• All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities;

• At the age of 18-70 years old;

• Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML);

• The patient has recovered from the toxicity of previous treatment;

• ECOG score ≤ 2 and expected survival period is not less than 3 months;

• Adequate organ function defined as:AST ≤3×ULN; ALT ≤3×ULN; Total bilirubin ≤1.5×ULN; Serum creatinine ≤1.5×ULN, or CCR≥60 mL/min; Hemoglobin ≥60g/L ; Indoor oxygen saturation ≥92%; LVEF≥45%;

• Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test;

• From the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception.